Role of P-glycoprotein in refractoriness of seizures to antiepileptic drugs in Lennox-Gastaut syndrome

Journal of Child Neurology

Volumn 30, Issue 2, 2015, Pages 223-227

  Kumar, Achal ^a   Tripathi, Deepak ^a   Paliwal, Vimal Kumar ^a   Neyaz, Zafar ^a   Agarwal, Vikas ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Lennox Gastaut syndrome; Multidrug resistance gene; P glycoprotein; Refractory epilepsy

Indexed keywords

ANTICONVULSIVE AGENT; MULTIDRUG RESISTANCE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; VERAPAMIL;

ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; EPILEPSY; FEMALE; HUMAN; LENNOX GASTAUT SYNDROME; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REFRACTORY PERIOD; SEIZURE; ADOLESCENT; BLOOD; DRUG EFFECTS; METABOLISM; MONONUCLEAR CELL; NONPARAMETRIC TEST; PRESCHOOL CHILD;

ADOLESCENT; ANTICONVULSANTS; CALCIUM CHANNEL BLOCKERS; CHILD; CHILD, PRESCHOOL; EPILEPSY; FEMALE; HUMANS; LENNOX GASTAUT SYNDROME; LEUKOCYTES, MONONUCLEAR; MALE; P-GLYCOPROTEIN; STATISTICS, NONPARAMETRIC; VERAPAMIL;

EID: 84927749696     PISSN: 08830738     EISSN: 17088283     Source Type: Journal    
DOI: 10.1177/0883073814532545     Document Type: Article

References (17)

1. Engel J Jr. ILAE classification of epilepsy syndromes. Epilepsy Res. 2006;70(suppl. 1): S5-S10.
2. Commision on classification and terminology of the international league against epilepsy. Proposed for revised classification of epilepsies and epileptic syndromes. Epilepsia. 1989;30:389-99.
3. Lennox WG, Davis JP. Clinical correlates of the fast and the slow spike wave electroencephalogram. Pediatrics. 1950;5:626-44.
4. Beaumanoir A, Blume W. The Lennox-Gastaut syndrome. In: Roger J, Bureau M, Dravet C, Genton P, Tassinari CA, Wolf P, eds. Epileptic syndromes in infancy, childhood and adolescence. Paris, France: John Libbey; 2005:125-148.
5. Arzimanoglou A, French J, Blume WT, et al. Lennox gastaut syndrome: a consensus approach to diagnosis, assessment, management and trial methodology. Lancet Neurol. 2009;8:82-9.
6. Loscher W, Schmidt D. New horizons in the development of antiepileptic drugs: the search for new targets. Epilepsy Res. 2004;60: 77-159
7. Löscher W, Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther. 2002;301:7-14.
8. Pendse S, Sayegh M.H, Frank MH. P-glycoprotein-a novel therapeutic target for immunomodulation in clinical transplantation and autoimmunity? Curr Drug Targets. 2003;4:469-476.
9. Dombrowski SM, Desai SY, Marroni M, et al. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 2001;42:1501-1506.
10. Ling V. Multidrug Resistance: molecular mechanism and clinical relevance [review]. Cancer Chemother Pharmacol. 1997;40: S3-S8.
11. Sisodiya SM, Lin WR, Squier MV, Thom M. Multidrug resistance protein 1 in focal cortical dysplasia. Lancet. 2001;357:42-43.
12. Sisodiya SM, Lin WR, Harding BN, et al. Drug Resistance in epilepsy: expression of drug resistance proteins in common cause of refractory epilepsy. Brain 2002;125:22-31.
13. Aronica E, Gorter JA, Jansen GH, et al. Expression and cellular distribution of multidrug transporter protein in two major causes of medically intractable epilepsy: focal cortical dysplasia and glioneural tumor. Neuroscience. 2003;118:417-429.
14. Tishler DM, Weinberg KI, Hinton DR, et al. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia. 1995;36:1-6.
15. Jose M, Thomas SV. Role of multidrug transporters in neurotherapeutics. Ann Indian Acad Neurol. 2009;12:89-98.
16. Sisodiya SM, Thom M. Widespread upregulation of drug resistance proteins in fatal human status epilepticus. Epilepsia. 2003;44:261-264.
17. Lazarowski A, Massaro M, Schteinschnaider A, et al. Neuronal MDR-1 gene expression and persistent low levels of anticonvulsants in a child with refractory epilepsy. Ther Drug Monitoring. 2004;26:44-46.